EUVIMEDEUVIMED entdecken
Crossref

Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom

Olga S Tatarinova iD, Philippa Woolley, Nilanthi Karawitage, Saravanan Vinayagam, Karen Logan, Catherin Ryu, George Adams, Carolyn Millar, Mike Laffan, Ferras Alwan, Deepa J Arachchillage

Seminars in Thrombosis and Hemostasis · 14.04.2026

DOI: 10.1055/a-2836-0591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 14.04.2026. Verfasst von Olga S Tatarinova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom. Gefördert von: Medical Research Council United Kingdom.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractAcquired haemophilia A (AHA) is an autoimmune bleeding disorder mediated by the production of autoantibody inhibitors against factor VIII (FVIII), resulting in a bleeding phenotype. The standard treatment of AHA includes immunosuppressive therapy for inhibitor eradication, haemostatic treatment with FVIII bypassing agents and treatment of underlying causes. Emicizumab is a bispecific monoclonal antibody that restores the function of missing activated FVIII by bridging FIXa and FX. Emicizumab is successfully used for prophylaxis of bleeding in congenital haemophilia A patients with or without FVIII inhibitors; however, it is not licensed for AHA treatment in the United Kingdom. We summarise our single-centre experience of the use of emicizumab for the treatment of AHA in 10 patients in the United Kingdom. Emicizumab was started at a dose of 3 mg/kg weekly with a change to fortnightly after the fourth dose. Eight patients received a combination of corticosteroids, emicizumab and rituximab; the remaining two, emicizumab and corticosteroids. In seven patients, emicizumab was stopped after achievement of an FVIII response and haemostasis following a median of 7 doses (3–53). In one patient, the treatment with emicizumab was complicated by the development of microangiopathic haemolytic anaemia. Three patients died, and in two of them, the death was associated with bleeding.

Autor:innen und Institutionen

  • Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • North West London Pathology, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.

ORCID-Profile: Olga S Tatarinova

Förderung

  • Medical Research Council United Kingdom

Zitieren

APA

Tatarinova, O. S., Woolley, P., Karawitage, N., Vinayagam, S., Logan, K., Ryu, C., Adams, G., Millar, C., Laffan, M., Alwan, F., & Arachchillage, D. J. (2026). Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/a-2836-0591

Vancouver

Tatarinova OS, Woolley P, Karawitage N, Vinayagam S, Logan K, Ryu C, et al. Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom. Seminars in Thrombosis and Hemostasis. 2026. doi:10.1055/a-2836-0591

BibTeX
@article{Tatarinova2026,
  author = {Tatarinova, Olga S and Woolley, Philippa and Karawitage, Nilanthi and Vinayagam, Saravanan and Logan, Karen and Ryu, Catherin and Adams, George and Millar, Carolyn and Laffan, Mike and Alwan, Ferras and Arachchillage, Deepa J},
  title = {Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  doi = {10.1055/a-2836-0591}
}
Kostenlos starten →